Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders

Abstract

(RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

1 . A method of prophylaxis and/or treatment of a hyperkinetic movement disorder comprising the steps of:
 administering a compound of formula (IA)   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof for prophylaxis and/or treatment of a hyperkinetic movement disorder to a subject in need thereof. 
     
     
         2 . (canceled) 
     
     
         3 . A method of prophylaxis and/or treatment of a hyperkinetic movement disorder comprising the steps of:
 administering a composition comprising a compound of formula (IA)   
       
         
           
           
               
               
           
         
       
       for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome and restless leg syndrome. 
     
     
         4 . The method of  claim 1 , wherein said prophylaxis or treatment comprises administering as a unique active ingredient the compound of formula (IA). 
     
     
         5 . The method of  claim 1 , wherein said prophylaxis or treatment comprises administering the compound of formula (IA) in combination therapy with an additional therapeutic agent selected from the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof;
 wherein:   the compound of formula (IB) is   
       
         
           
           
               
               
           
         
       
       and the compound of formula (IC) is 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method of  claim 5 , wherein the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (IA) and the additional therapeutic agent. 
     
     
         7 . The method of  claim 5 , wherein the additional therapeutic agent is selected from the group consisting of a compound of formula (IB), a compound of formula (IC), amantadine, riluzole, tetrabenazine, reserpine, and donepezil. 
     
     
         8 . The method of  claim 3  further comprising the step of combining the compound of formula (IA) and an additional therapeutic agent selected from the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof; wherein:
 the compound of formula (IB) is 
 
       
         
           
           
               
               
           
         
       
       and the compound of formula (IC) is 
       
         
           
           
               
               
           
         
       
     
     
         9 . The method of  claim 1 , further comprising combining an additional therapeutic agent. 
     
     
         10 . The method of  claim 1 , wherein the hyperkinetic movement disorder is selected from the group consisting of abdominal dyskinesias, akathisic movements, asynergia, ataxia, athetosis, ballism, chorea, dysmetria, dystonia, hemifacial spasm, hyperekplexia, hypnogenic dyskinesias, jumpy stumps, moving toes and/or fingers, myoclonus, myokymia, myorhythmia, paroxysmal dyskinesias, tics, and tremors. 
     
     
         11 . The method of  claim 1 , wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia. 
     
     
         12 . The method of  claim 1 , wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease. 
     
     
         13 . The method of  claim 1 , wherein the hyperkinetic movement disorder is tics associated to Tourette syndrome and tardive dyskinesia. 
     
     
         14 . The method of  claim 1 , wherein the hyperkinetic movement disorder is ballism. 
     
     
         15 . The method of  claim 1 , wherein the hyperkinetic movement disorder is dystonia. 
     
     
         16 . The method of  claim 1  as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers. 
     
     
         17 . The method of  claim 16 , wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form. 
     
     
         18 . The method of  claim 8 , wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia. 
     
     
         19 . The combination for use according to  claim 8 , wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease. 
     
     
         20 . The combination for use according to  claim 8 , as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers. 
     
     
         21 . The combination for use according to  claim 20 , wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, or topical unit dosage form.